167 related articles for article (PubMed ID: 32810922)
1. Upregulation of CIP2A in estrogen depletion-resistant breast cancer cells treated with low-dose everolimus.
Nishio E; Hayashi T; Akaza M; Hisatomi Y; Hikichi M; Fujii T; Utsumi T; Harada N; Shimono Y
FEBS Open Bio; 2020 Oct; 10(10):2072-2080. PubMed ID: 32810922
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
[TBL] [Abstract][Full Text] [Related]
3. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
4. Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells.
Hayashi T; Hikichi M; Yukitake J; Wakatsuki T; Nishio E; Utsumi T; Harada N
Oncotarget; 2018 May; 9(34):23451-23461. PubMed ID: 29805747
[TBL] [Abstract][Full Text] [Related]
5. Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis.
Zhang Y; Huang P; Liu X; Xiang Y; Zhang T; Wu Y; Xu J; Sun Z; Zhen W; Zhang L; Si Y; Liu Y
J Pharmacol Sci; 2018 Jul; 137(3):305-312. PubMed ID: 30119963
[TBL] [Abstract][Full Text] [Related]
6. Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells.
Zhao Q; Zhao M; Parris AB; Xing Y; Yang X
Int J Oncol; 2016 Sep; 49(3):1203-10. PubMed ID: 27574003
[TBL] [Abstract][Full Text] [Related]
7. Estradiol enhances CIP2A expression by the activation of p70 S6 kinase.
Choi YA; Koo JS; Park JS; Park MY; Jeong AL; Oh KS; Yang Y
Endocr Relat Cancer; 2014 Apr; 21(2):189-202. PubMed ID: 24280132
[TBL] [Abstract][Full Text] [Related]
8. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression.
Guo B; Wu S; Zhu X; Zhang L; Deng J; Li F; Wang Y; Zhang S; Wu R; Lu J; Zhou Y
EMBO J; 2020 Jan; 39(1):e102190. PubMed ID: 31755573
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/adriamycin cells.
Cai F; Zhang L; Xiao X; Duan C; Huang Q; Fan C; Li J; Liu X; Li S; Liu Y
Oncol Rep; 2016 Aug; 36(2):1180-6. PubMed ID: 27350399
[TBL] [Abstract][Full Text] [Related]
10. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.
Laine A; Sihto H; Come C; Rosenfeldt MT; Zwolinska A; Niemelä M; Khanna A; Chan EK; Kähäri VM; Kellokumpu-Lehtinen PL; Sansom OJ; Evan GI; Junttila MR; Ryan KM; Marine JC; Joensuu H; Westermarck J
Cancer Discov; 2013 Feb; 3(2):182-97. PubMed ID: 23306062
[TBL] [Abstract][Full Text] [Related]
11. Depletion of CIP2A inhibits the proliferation, migration, invasion and epithelial-mesenchymal transition of glioma cells.
Xu Z; Chen X; Hegazy AM; Zhang S; Liu X; Tian J; Wu J; Shi F; Li L; Niu X; Pu J
Brain Res Bull; 2021 Aug; 173():14-21. PubMed ID: 33892085
[TBL] [Abstract][Full Text] [Related]
12. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
[TBL] [Abstract][Full Text] [Related]
13. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
[TBL] [Abstract][Full Text] [Related]
14. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
15. p90/CIP2A mediates breast cancer cell proliferation and apoptosis.
Liu X; Peng B; Li Y; Lei N; Li W; Zhang JY
Mol Biol Rep; 2014 Nov; 41(11):7471-8. PubMed ID: 25086622
[TBL] [Abstract][Full Text] [Related]
16. Increase in CIP2A expression is associated with doxorubicin resistance.
Choi YA; Park JS; Park MY; Oh KS; Lee MS; Lim JS; Kim KI; Kim KY; Kwon J; Yoon DY; Moon EY; Yang Y
FEBS Lett; 2011 Mar; 585(5):755-60. PubMed ID: 21241697
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.
Liu N; He QM; Chen JW; Li YQ; Xu YF; Ren XY; Sun Y; Mai HQ; Shao JY; Jia WH; Kang TB; Zeng MS; Ma J
Mol Cancer; 2014 May; 13():111. PubMed ID: 24884612
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism.
Wang HW; Yang SH; Huang GD; Lin JK; Chen WS; Jiang JK; Lan YT; Lin CC; Hwang WL; Tzeng CH; Li AF; Yen CC; Teng HW
J Cancer Res Clin Oncol; 2014 Apr; 140(4):561-71. PubMed ID: 24493623
[TBL] [Abstract][Full Text] [Related]
19. CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer.
Lei N; Peng B; Zhang JY
Oncol Rep; 2014 Oct; 32(4):1689-94. PubMed ID: 25109354
[TBL] [Abstract][Full Text] [Related]
20. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]